Oppenheimer & Co. Inc. purchased a new position in shares of Nevro Corp. (NYSE:NVRO) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 16,623 shares of the medical equipment provider’s stock, valued at approximately $1,237,000. Oppenheimer & Co. Inc. owned approximately 0.06% of Nevro Corp. as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of NVRO. BlackRock Inc. raised its stake in shares of Nevro Corp. by 76,628.7% during the first quarter. BlackRock Inc. now owns 1,575,240 shares of the medical equipment provider’s stock worth $147,602,000 after acquiring an additional 1,573,187 shares in the last quarter. Jennison Associates LLC raised its stake in shares of Nevro Corp. by 67.5% during the second quarter. Jennison Associates LLC now owns 1,139,119 shares of the medical equipment provider’s stock worth $84,785,000 after acquiring an additional 458,925 shares in the last quarter. Victory Capital Management Inc. purchased a new position in shares of Nevro Corp. during the first quarter worth approximately $26,784,000. Perceptive Advisors LLC purchased a new position in shares of Nevro Corp. during the first quarter worth approximately $20,360,000. Finally, Janus Capital Management LLC raised its stake in shares of Nevro Corp. by 40.6% during the first quarter. Janus Capital Management LLC now owns 602,049 shares of the medical equipment provider’s stock worth $56,409,000 after acquiring an additional 173,954 shares in the last quarter.

Nevro Corp. (NYSE:NVRO) opened at 88.35 on Friday. Nevro Corp. has a 52 week low of $65.82 and a 52 week high of $106.93. The stock’s market capitalization is $2.60 billion. The company has a 50 day moving average of $85.10 and a 200 day moving average of $84.52.

Nevro Corp. (NYSE:NVRO) last released its quarterly earnings results on Monday, August 7th. The medical equipment provider reported ($0.40) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by $0.11. Nevro Corp. had a negative net margin of 14.33% and a negative return on equity of 16.25%. The company had revenue of $78.02 million for the quarter, compared to analysts’ expectations of $77.75 million. During the same quarter in the previous year, the company posted ($0.31) EPS. The business’s quarterly revenue was up 40.8% on a year-over-year basis. Equities analysts expect that Nevro Corp. will post ($1.16) EPS for the current fiscal year.

Several research firms have commented on NVRO. B. Riley downgraded shares of Nevro Corp. to a “neutral” rating and set a $85.00 price target on the stock. in a research note on Sunday, May 14th. Northland Securities reissued a “buy” rating and set a $96.00 price target on shares of Nevro Corp. in a research note on Tuesday, August 8th. BMO Capital Markets reissued a “buy” rating and set a $106.00 price target on shares of Nevro Corp. in a research note on Friday, September 1st. Morgan Stanley lifted their price target on shares of Nevro Corp. from $87.00 to $95.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 8th. Finally, J P Morgan Chase & Co reissued an “overweight” rating and set a $102.00 price target on shares of Nevro Corp. in a research note on Monday, July 3rd. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $101.25.

COPYRIGHT VIOLATION WARNING: This story was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/09/09/oppenheimer-co-inc-purchases-shares-of-16623-nevro-corp-nvro.html.

In related news, Director Wilfred E. Jaeger sold 79,657 shares of the stock in a transaction on Wednesday, August 16th. The stock was sold at an average price of $82.74, for a total transaction of $6,590,820.18. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Andrew H. Galligan sold 7,000 shares of the stock in a transaction on Monday, August 14th. The shares were sold at an average price of $82.31, for a total value of $576,170.00. The disclosure for this sale can be found here. Insiders have sold a total of 234,440 shares of company stock worth $19,619,157 in the last 90 days. 12.10% of the stock is currently owned by insiders.

Nevro Corp. Profile

Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Institutional Ownership by Quarter for Nevro Corp. (NYSE:NVRO)

Receive News & Stock Ratings for Nevro Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp. and related stocks with our FREE daily email newsletter.